ATE493124T1 - Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren - Google Patents

Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren

Info

Publication number
ATE493124T1
ATE493124T1 AT00925997T AT00925997T ATE493124T1 AT E493124 T1 ATE493124 T1 AT E493124T1 AT 00925997 T AT00925997 T AT 00925997T AT 00925997 T AT00925997 T AT 00925997T AT E493124 T1 ATE493124 T1 AT E493124T1
Authority
AT
Austria
Prior art keywords
inflammatory response
mammals
composition
inflammatory reaction
treating inflammatory
Prior art date
Application number
AT00925997T
Other languages
English (en)
Inventor
Stanley Katz
Alain Martin
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Application granted granted Critical
Publication of ATE493124T1 publication Critical patent/ATE493124T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00925997T 1999-05-14 2000-04-14 Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren ATE493124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31216899A 1999-05-14 1999-05-14
PCT/US2000/010062 WO2000069431A1 (en) 1999-05-14 2000-04-14 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response

Publications (1)

Publication Number Publication Date
ATE493124T1 true ATE493124T1 (de) 2011-01-15

Family

ID=23210184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00925997T ATE493124T1 (de) 1999-05-14 2000-04-14 Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren

Country Status (11)

Country Link
EP (1) EP1183022B1 (de)
JP (2) JP4885362B2 (de)
AT (1) ATE493124T1 (de)
AU (1) AU772148B2 (de)
CA (1) CA2373611C (de)
DE (1) DE60045445D1 (de)
IL (1) IL146391A0 (de)
MX (1) MXPA01011521A (de)
NZ (1) NZ515364A (de)
WO (1) WO2000069431A1 (de)
ZA (1) ZA200109377B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528307A (ja) 2001-03-15 2004-09-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法
WO2006003492A2 (en) * 2004-07-02 2006-01-12 Warner-Lambert Company Llc Compositions and methods for treating pathological infections
CA2910825A1 (en) * 2013-03-28 2014-10-02 Pharmacaribe, Llc Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions
US12611389B1 (en) * 2025-08-15 2026-04-28 Cellular Sciences, Inc. Compositions and methods to reduce or eliminate nasal biofilms and mucus barriers allowing sodium pyruvate to increase the synthesis of nitric oxide and eliminate nasal infections and their toxins that cause lung, nerve and brain damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
AU1093195A (en) * 1993-11-19 1995-06-06 Schering-Plough Healthcare Products, Inc. Nasal spray compositions containing oxymetazoline
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
JPH101442A (ja) * 1996-06-12 1998-01-06 Taisho Pharmaceut Co Ltd 鼻炎用点鼻薬

Also Published As

Publication number Publication date
AU772148B2 (en) 2004-04-08
JP4885362B2 (ja) 2012-02-29
JP2011190274A (ja) 2011-09-29
WO2000069431A1 (en) 2000-11-23
MXPA01011521A (es) 2003-08-20
AU4460200A (en) 2000-12-05
CA2373611C (en) 2009-06-23
NZ515364A (en) 2004-05-28
EP1183022A1 (de) 2002-03-06
EP1183022A4 (de) 2004-12-08
JP2002544228A (ja) 2002-12-24
IL146391A0 (en) 2002-07-25
EP1183022B1 (de) 2010-12-29
DE60045445D1 (de) 2011-02-10
CA2373611A1 (en) 2000-11-23
ZA200109377B (en) 2002-11-07

Similar Documents

Publication Publication Date Title
EA200400595A1 (ru) Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы
EA200001176A1 (ru) Гетероциклические ингибиторы p38
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
ATE356113T1 (de) Probucolbernsteinsäureester zur hemmung der expression von vcam-1
DE60232234D1 (de) Verfahren zur kultivierung von circovirus
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
DK1017692T3 (da) 4-Heteroaryl-tetrahydroquinoliner og deres anvendelse som inhibitorer af cholesterolester-transferproteiner
CR10967A (es) Formas polimorficas de 3-(4-amino-1-oxo-1,3 dihidro-isoindol-2-il) piperidina-2,6-diona (divisional exp. 8291)
PT1268445E (pt) Derivados de 4-amino-5-ciano-2-anilino-pirimidina e sua utilizacao como inibidores de cinases do ciclo celular
ATE501264T1 (de) Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
BR0116402A (pt) Derivados de tetrahidropiridina, sua preparação e sua utilização como inibidores de proliferação celular
HRP20041005B1 (hr) Kinolinski i izokinolinski derivati, postupci njihove proizvodnje, te naäśini njihove primjene kao sredstava za spreäśavanje (suzbijanje) upalnih procesa
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
DE69514798D1 (de) Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten
CR7807A (es) Piperacinil y diacepanil benzamidas y benztioamidas
MX9703653A (es) Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria.
HUP0203385A2 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
WO2001092253A3 (en) Inhibitors of alpha l beta 2 mediated cell adhesion
DE60045445D1 (de) Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren
MY135375A (en) Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
ATE187461T1 (de) Cyklopeptolide
NO20053089L (no) Carbamidsyreestere med anticolinergisk virkning.
ATE406461T1 (de) Rna-bioassay
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties